BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li M, Chen X, Chen L, Chen K, Zhou J, Song J. MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCM. J Transl Med 2018;16:161. [PMID: 29885652 DOI: 10.1186/s12967-018-1534-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Chiti E, Paolo MD, Turillazzi E, Rocchi A. MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy. Diagnostics (Basel) 2021;11:1720. [PMID: 34574061 DOI: 10.3390/diagnostics11091720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hosseini M, Sahebi R, Aghasizadeh M, Yazdi DF, Salaribaghoonabad R, Godsi A, Soflaei SS, Mousavitaherabad SP, Ahmadihoseini A, Bajgiran MM, Ferns GA, Darban RA, Mobarhan MG. Investigating the predictive value of microRNA21 as a biomarker in induced myocardial infarction animal model. Gene Reports 2022. [DOI: 10.1016/j.genrep.2022.101578] [Reference Citation Analysis]
3 Chatzopoulou F, Kyritsis KA, Papagiannopoulos CI, Galatou E, Mittas N, Theodoroula NF, Papazoglou AS, Karagiannidis E, Chatzidimitriou M, Papa A, Sianos G, Angelis L, Chatzidimitriou D, Vizirianakis IS. Dissecting miRNA–Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine. Cells 2022;11:607. [DOI: 10.3390/cells11040607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wang Z, Xia Q, Su W, Cao M, Sun Y, Zhang M, Chen W, Jiang T. Exploring the Communal Pathogenesis, Ferroptosis Mechanism, and Potential Therapeutic Targets of Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy via a Microarray Data Analysis. Front Cardiovasc Med 2022;9:824756. [DOI: 10.3389/fcvm.2022.824756] [Reference Citation Analysis]
5 Calderon-dominguez M, Mangas A, Belmonte T, Quezada-feijoo M, Ramos M, Toro R. Fisiopatología de la miocardiopatía dilatada isquémica a través del microRNA-16-5p. Revista Española de Cardiología 2021;74:740-9. [DOI: 10.1016/j.recesp.2020.08.030] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Wu X, Huang L, Liu J. Relationship between oxidative stress and nuclear factor-erythroid-2-related factor 2 signaling in diabetic cardiomyopathy (Review). Exp Ther Med 2021;22:678. [PMID: 33986843 DOI: 10.3892/etm.2021.10110] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cardenas J, Balaji U, Gu J. Cerina: systematic circRNA functional annotation based on integrative analysis of ceRNA interactions. Sci Rep 2020;10:22165. [PMID: 33335165 DOI: 10.1038/s41598-020-78469-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Feng W, Han S, Mladenka P. lncRNA ADAMTS9-AS1/circFN1 Competitively Binds to miR-206 to Elevate the Expression of ACTB, Thus Inducing Hypertrophic Cardiomyopathy. Oxidative Medicine and Cellular Longevity 2022;2022:1-13. [DOI: 10.1155/2022/1450610] [Reference Citation Analysis]
9 Thottakara T, Lund N, Krämer E, Kirchhof P, Carrier L, Patten M. A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy. Biomolecules 2021;11:1718. [PMID: 34827715 DOI: 10.3390/biom11111718] [Reference Citation Analysis]
10 Rabajdova M, Spakova I, Zelko A, Rosenberger J, Kolarcik P, Sobolova V, Pella D, Marekova M, Madarasova Geckova A. The role of physical activity and miRNAs in the vascular aging and cardiac health of dialysis patients. Physiol Rep 2021;9:e14879. [PMID: 34042291 DOI: 10.14814/phy2.14879] [Reference Citation Analysis]
11 Colpaert RMW, Calore M. MicroRNAs in Cardiac Diseases. Cells 2019;8:E737. [PMID: 31323768 DOI: 10.3390/cells8070737] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 18.0] [Reference Citation Analysis]
12 Zhang H, Zhang Z, Gao L, Qiao Z, Yu M, Yu B, Yang T. miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9. Onco Targets Ther 2019;12:2149-57. [PMID: 30962696 DOI: 10.2147/OTT.S197326] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
13 Surina S, Fontanella RA, Scisciola L, Marfella R, Paolisso G, Barbieri M. miR-21 in Human Cardiomyopathies. Front Cardiovasc Med 2021;8:767064. [PMID: 34778418 DOI: 10.3389/fcvm.2021.767064] [Reference Citation Analysis]
14 Ntelios D, Georgiou E, Alexouda S, Malousi A, Efthimiadis G, Tzimagiorgis G. A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy. Heart Fail Rev 2021. [PMID: 33656618 DOI: 10.1007/s10741-021-10084-y] [Reference Citation Analysis]
15 Calderon-Dominguez M, Mangas A, Belmonte T, Quezada-Feijoo M, Ramos M, Toro R. Ischemic dilated cardiomyopathy pathophysiology through microRNA-16-5p. Rev Esp Cardiol (Engl Ed) 2021;74:740-9. [PMID: 33051165 DOI: 10.1016/j.rec.2020.08.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Sigutova R, Evin L, Stejskal D, Ploticova V, Svagera Z. Specific microRNAs and heart failure: time for the next step toward application? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2022. [PMID: 35726831 DOI: 10.5507/bp.2022.028] [Reference Citation Analysis]
17 Hua TR, Zhang SY. Cardiomyopathies in China: A 2018-2019 state-of-the-art review. Chronic Dis Transl Med 2020;6:224-38. [PMID: 33336168 DOI: 10.1016/j.cdtm.2020.05.006] [Reference Citation Analysis]
18 Kamburov A, Herwig R. ConsensusPathDB 2022: molecular interactions update as a resource for network biology. Nucleic Acids Res 2021:gkab1128. [PMID: 34850110 DOI: 10.1093/nar/gkab1128] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tao L, Shi J, Huang X, Hua F, Yang L. Identification of a lncRNA-miRNA-mRNA network based on competitive endogenous RNA theory reveals functional lncRNAs in hypertrophic cardiomyopathy. Exp Ther Med 2020;20:1176-90. [PMID: 32742356 DOI: 10.3892/etm.2020.8748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Calderon-Dominguez M, Belmonte T, Quezada-Feijoo M, Ramos-Sánchez M, Fernández-Armenta J, Pérez-Navarro A, Cesar S, Peña-Peña L, Vea À, Llorente-Cortés V, Mangas A, de Gonzalo-Calvo D, Toro R. Emerging role of microRNAs in dilated cardiomyopathy: evidence regarding etiology. Transl Res 2020;215:86-101. [PMID: 31505160 DOI: 10.1016/j.trsl.2019.08.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
21 Chen H, Bao L, Hu J, Wu D, Tong X. ORC6, Negatively Regulated by miR-1-3p, Promotes Proliferation, Migration, and Invasion of Hepatocellular Carcinoma Cells. Front Cell Dev Biol 2021;9:652292. [PMID: 34395415 DOI: 10.3389/fcell.2021.652292] [Reference Citation Analysis]
22 He R, Ding C, Yin P, He L, Xu Q, Wu Z, Shi Y, Su L. MiR-1a-3p mitigates isoproterenol-induced heart failure by enhancing the expression of mitochondrial ND1 and COX1. Exp Cell Res 2019;378:87-97. [PMID: 30853447 DOI: 10.1016/j.yexcr.2019.03.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
23 Kura B, Kalocayova B, Devaux Y, Bartekova M. Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection. Int J Mol Sci 2020;21:E700. [PMID: 31973111 DOI: 10.3390/ijms21030700] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]